Cargando…
In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
PURPOSE: Histone deacetylase inhibitors are promising new substances in cancer therapy and have also been shown to sensitize different tumor cells to irradiation (XRT). We explored the effect as well as the radiosensitizing properties of suberoylanilide hydroxamic acid (SAHA) in vivo in a malignant...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342162/ https://www.ncbi.nlm.nih.gov/pubmed/22458853 http://dx.doi.org/10.1186/1748-717X-7-52 |
_version_ | 1782231644438003712 |
---|---|
author | Thiemann, Markus Oertel, Susanne Ehemann, Volker Weichert, Wilko Stenzinger, Albrecht Bischof, Marc Weber, Klaus-J Perez, Ramon Lopez Haberkorn, Uwe Kulozik, Andreas E Debus, Jürgen Huber, Peter E Battmann, Claudia |
author_facet | Thiemann, Markus Oertel, Susanne Ehemann, Volker Weichert, Wilko Stenzinger, Albrecht Bischof, Marc Weber, Klaus-J Perez, Ramon Lopez Haberkorn, Uwe Kulozik, Andreas E Debus, Jürgen Huber, Peter E Battmann, Claudia |
author_sort | Thiemann, Markus |
collection | PubMed |
description | PURPOSE: Histone deacetylase inhibitors are promising new substances in cancer therapy and have also been shown to sensitize different tumor cells to irradiation (XRT). We explored the effect as well as the radiosensitizing properties of suberoylanilide hydroxamic acid (SAHA) in vivo in a malignant rhabdoid tumor (MRT) mouse model. METHODS AND MATERIAL: Potential radiosensitization by SAHA was assessed in MRT xenografts by analysis of tumor growth delay, necrosis (HE), apoptosis (TUNEL), proliferation (ki-67) and γH2AX expression as well as dynamic (18)F-Fluorodeoxyglucose Positron Emission Tomography ((18)F-FDG -PET) after treatment with either SAHA alone, single-dose (10 Gy) or fractionated XRT (3 × 3Gy) solely as well as in combination with SAHA compared to controls. RESULTS: SAHA only had no significant effect on tumor growth. Combination of SAHA for 8 days with single-dose XRT resulted in a higher number of complete remissions, but failed to prove a significant growth delay compared to XRT only. In contrast fractionated XRT plus SAHA for 3 weeks did induce significant tumor growth delay in MRT-xenografts. The histological examination showed a significant effect of XRT in tumor necrosis, expression of Ki-67, γH2AX and apoptosis. SAHA only had no significant effect in the histological examination. Comparison of xenografts treated with XRT and XRT plus SAHA revealed a significantly increased γH2AX expression and apoptosis induction in the mice tumors after combination treatment with single-dose as well as fractionated XRT. The combination of SAHA with XRT showed a tendency to increased necrosis and decrease of proliferation compared to XRT only, which, however, was not significant. The (18)F-FDG-PET results showed no significant differences in the standard uptake value or glucose transport kinetics after either treatment. CONCLUSION: SAHA did not have a significant effect alone, but proved to enhance the effect of XRT in our MRT in vivo model. |
format | Online Article Text |
id | pubmed-3342162 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-33421622012-05-03 In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model Thiemann, Markus Oertel, Susanne Ehemann, Volker Weichert, Wilko Stenzinger, Albrecht Bischof, Marc Weber, Klaus-J Perez, Ramon Lopez Haberkorn, Uwe Kulozik, Andreas E Debus, Jürgen Huber, Peter E Battmann, Claudia Radiat Oncol Research PURPOSE: Histone deacetylase inhibitors are promising new substances in cancer therapy and have also been shown to sensitize different tumor cells to irradiation (XRT). We explored the effect as well as the radiosensitizing properties of suberoylanilide hydroxamic acid (SAHA) in vivo in a malignant rhabdoid tumor (MRT) mouse model. METHODS AND MATERIAL: Potential radiosensitization by SAHA was assessed in MRT xenografts by analysis of tumor growth delay, necrosis (HE), apoptosis (TUNEL), proliferation (ki-67) and γH2AX expression as well as dynamic (18)F-Fluorodeoxyglucose Positron Emission Tomography ((18)F-FDG -PET) after treatment with either SAHA alone, single-dose (10 Gy) or fractionated XRT (3 × 3Gy) solely as well as in combination with SAHA compared to controls. RESULTS: SAHA only had no significant effect on tumor growth. Combination of SAHA for 8 days with single-dose XRT resulted in a higher number of complete remissions, but failed to prove a significant growth delay compared to XRT only. In contrast fractionated XRT plus SAHA for 3 weeks did induce significant tumor growth delay in MRT-xenografts. The histological examination showed a significant effect of XRT in tumor necrosis, expression of Ki-67, γH2AX and apoptosis. SAHA only had no significant effect in the histological examination. Comparison of xenografts treated with XRT and XRT plus SAHA revealed a significantly increased γH2AX expression and apoptosis induction in the mice tumors after combination treatment with single-dose as well as fractionated XRT. The combination of SAHA with XRT showed a tendency to increased necrosis and decrease of proliferation compared to XRT only, which, however, was not significant. The (18)F-FDG-PET results showed no significant differences in the standard uptake value or glucose transport kinetics after either treatment. CONCLUSION: SAHA did not have a significant effect alone, but proved to enhance the effect of XRT in our MRT in vivo model. BioMed Central 2012-03-29 /pmc/articles/PMC3342162/ /pubmed/22458853 http://dx.doi.org/10.1186/1748-717X-7-52 Text en Copyright ©2012 Thiemann et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Thiemann, Markus Oertel, Susanne Ehemann, Volker Weichert, Wilko Stenzinger, Albrecht Bischof, Marc Weber, Klaus-J Perez, Ramon Lopez Haberkorn, Uwe Kulozik, Andreas E Debus, Jürgen Huber, Peter E Battmann, Claudia In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model |
title | In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model |
title_full | In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model |
title_fullStr | In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model |
title_full_unstemmed | In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model |
title_short | In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model |
title_sort | in vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342162/ https://www.ncbi.nlm.nih.gov/pubmed/22458853 http://dx.doi.org/10.1186/1748-717X-7-52 |
work_keys_str_mv | AT thiemannmarkus invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel AT oertelsusanne invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel AT ehemannvolker invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel AT weichertwilko invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel AT stenzingeralbrecht invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel AT bischofmarc invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel AT weberklausj invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel AT perezramonlopez invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel AT haberkornuwe invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel AT kulozikandrease invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel AT debusjurgen invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel AT huberpetere invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel AT battmannclaudia invivoefficacyofthehistonedeacetylaseinhibitorsuberoylanilidehydroxamicacidincombinationwithradiotherapyinamalignantrhabdoidtumormousemodel |